A New Challenge for TP53 and RAS-Mutated Hematological Cancers

The National Cancer Institute (NCI) has initiated a Phase 1 clinical trial (NCT06904066) for a personalized TCR-T therapy targeting the tumor suppressor gene TP53 and Ras (NRAS, KRAS, HRAS) mutations. TP53 and RAS mutations are considered 'undruggable' genes and are associated with extremely poor prognoses in patients with hematological malignancies. For patients who have failed even hematopoietic stem cell transplantation, T-cell receptor (TCR)-based therapy, which targets intracellular mutated proteins, represents an advancement in precision medicine.

The industry is closely watching to see if this therapy can demonstrate meaningful safety and clinical efficacy in these difficult-to-treat hematological cancers, where there is a high unmet need.

Genetic Engineering Innovation in Personalized Neoantigen Targeting

This trial employs a method of introducing TCR genes that recognize a patient's unique neoepitopes into the patient's T cells via a gamma-retroviral vector. A personalized TCR library is matched to the patient's major histocompatibility complex (HLA-A02:01, A11:01, etc.) type and genetically modified. This approach overcomes the limitations of existing chimeric antigen receptor T-cell (CAR-T) therapies, which only target cell surface proteins, by targeting intracellular mutated proteins. This will be an opportunity to validate the technical reliability of next-generation immune cell therapies based on patient-specific cancer genomic analysis.

Technical Hurdles in Complex Manufacturing and Combination Therapy

Patients will receive lymphodepleting chemotherapy with cyclophosphamide and fludarabine before receiving T-cell infusion. High-dose aldesleukin (IL-2) is co-administered to promote cell proliferation, but this carries the risk of severe toxicities such as cytokine release syndrome (CRS). In addition, the complex and costly autologous manufacturing process of extracting and genetically modifying patient-derived T cells needs to be addressed. Overcoming these hurdles will be key to the platform's commercialization.

Creating Market Value by Addressing Unmet Needs

The global acute myeloid leukemia (AML) market is projected to grow to $10.6 billion by 2035, and the myelodysplastic syndrome (MDS) market is projected to grow to $11.2 billion. Hematological cancers with TP53/RAS mutations represent a large unmet market with few effective treatment options. The success of this trial will demonstrate that TCR-T technology can be a powerful therapeutic platform not only for solid tumors but also for difficult-to-treat hematological cancers. This is expected to be a major catalyst for global venture capital (VC) firms and pharmaceutical companies to make large investments in next-generation immune cell therapy pipelines.

Verifying Long-Term Safety and Securing Platform Competitiveness

The NCI researchers plan to conduct long-term follow-up studies for up to 10 years to closely monitor the safety and in vivo persistence of the gene-modified T cells. The process of identifying long-term risks, such as insertional mutagenesis due to the use of retroviral vectors, will be an important criterion for regulatory approval. The results of this trial will provide important milestones for the clinical trial design of global biotech companies such as Immatics (IMTX) and Adaptimmune (ADAP), which are developing commercial TCR-T therapies. Securing independent gene editing technology and a safety profile will be key to determining market dominance in the future.